Real-world data from Uruguay (almost 100% P.1 epidemic nowadays) show two dozes of the Pfizer vaccine is 75% effective against symptomatic cases and 99% against hospitalization. CoronaVac, which is also applied there, stood at a still-respectable 57% and 95%, respectively. The latter is fairly consistent with Chile, where the variant also predominates, at 65% and 89%, respectively, for CoronaVac, with data for Pfizer to be released soon.